Clinical Trials Directory

Trials / Completed

CompletedNCT00162708

Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC

A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
120 (planned)
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
Sex
All
Age
40 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Altered fractionated radiotherapy and concomitant radio-chemotherapy have been shown to be two possibilities for improving efficacy of radiotherapy in locally advanced head and neck carcinomas. In this multicentric study, we tested the hypothesis that accelerated radiotherapy could be delivered concomitantly with conventional high doses of CDDP-5FU, aiming to improve both local control and on distant metastases as compared to very accelerated radiotherapy.

Detailed description

Patients with a palpable N2b-c or N3 HNSCC strictly unresectable were randomized to receive either accelerated RT-CT delivering to the primary tumor 62-64 Gy / 5 weeks in 31-32 fractions of 2 Gy BID or very accelerated RT delivering 62-64 Gy in 31-32 fractions of 2 Gy BID and 22-23 days. In the accelerated RT-CT arm, 3 cycles of CDDP 100 mg/m2 were delivered at day 1, 16, 32 and 2 cycles of 5 Fu 1000 mg/m2 day 1 to 5 and 31 to 35. One month after completion of the concomitant RT-CT, 2 additional cycles of CDDP-5FU were given in patients responding (\> 50%) to the initial course of RT-CT. The end points were event free survival and survival.

Conditions

Interventions

TypeNameDescription
PROCEDURERadiotherapy 62-64 Gy in 5 W (31-32 f. of 2 Gy BID)
PROCEDURERadiotherapy 62-64 Gy in 22-23 D (31-32 f of 2 Gy BID)
DRUGCDDP, 5 Fu

Timeline

Start date
1996-07-01
First posted
2005-09-13
Last updated
2005-09-13

Locations

3 sites across 1 country: France

Source: ClinicalTrials.gov record NCT00162708. Inclusion in this directory is not an endorsement.